These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 33205694

  • 1. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M, Efficace F, Colafigli G, Scalzulli E, Di Prima A, Martelli M, Foà R.
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 4. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J, Rea D, Lipton JH.
    Am J Hematol; 2019 Mar 15; 94(3):346-357. PubMed ID: 30394563
    [Abstract] [Full Text] [Related]

  • 5. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S, Tremblay D, Mascarenhas J.
    Clin Lymphoma Myeloma Leuk; 2016 Sep 15; 16(9):488-494. PubMed ID: 27406834
    [Abstract] [Full Text] [Related]

  • 6. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L, Akard LP.
    Leuk Lymphoma; 2016 Dec 15; 57(12):2739-2751. PubMed ID: 27562641
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
    Elsayed AG, Srivastava R, Jamil MO.
    Curr Oncol Rep; 2017 Oct 07; 19(12):77. PubMed ID: 28988389
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.
    Clark RE.
    Curr Hematol Malig Rep; 2019 Dec 07; 14(6):507-514. PubMed ID: 31701369
    [Abstract] [Full Text] [Related]

  • 10. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
    Breccia M, Foà R.
    Curr Oncol Rep; 2018 Mar 06; 20(3):23. PubMed ID: 29511948
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E, Torregrosa-Diaz J, Gallego-Hernanz P, Tartarin F, Systchenko T, Maillard N, Desmier D, Machet A, Fleck E, Corby A, Motard C, Denis G, Herbelin A, Gombert JM, Roy L, Ragot S, Leleu X, Guilhot F, Chomel JC.
    Cancer; 2020 Aug 01; 126(15):3438-3447. PubMed ID: 32459375
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT, Cortes JE, Kantarjian HM.
    Lancet Haematol; 2019 Aug 01; 6(8):e398-e408. PubMed ID: 31208943
    [Abstract] [Full Text] [Related]

  • 16. On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?
    Stagno F, Breccia M, Di Raimondo F.
    Expert Rev Anticancer Ther; 2020 Dec 01; 20(12):1075-1081. PubMed ID: 32985290
    [Abstract] [Full Text] [Related]

  • 17. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
    Stella S, Tirró E, Massimino M, Vitale SR, Russo S, Pennisi MS, Puma A, Romano C, DI Gregorio S, Innao V, Stagno F, DI Raimondo F, Musolino C, Manzella L.
    In Vivo; 2019 Dec 01; 33(5):1593-1598. PubMed ID: 31471409
    [Abstract] [Full Text] [Related]

  • 18. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.
    Ross DM, Hughes TP.
    Br J Haematol; 2014 Jul 01; 166(1):3-11. PubMed ID: 24754670
    [Abstract] [Full Text] [Related]

  • 19. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
    Dulucq S, Mahon FX.
    Cancer Med; 2016 Sep 01; 5(9):2398-411. PubMed ID: 27367039
    [Abstract] [Full Text] [Related]

  • 20. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
    Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP, Australasian Leukaemia and Lymphoma Group (ALLG).
    Leukemia; 2018 Dec 01; 32(12):2572-2579. PubMed ID: 30315232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.